Lemildipine (NB-818)
(Synonyms: 来米地平,NB-818; NPK-1886) 目录号 : GC32533
Lemildipine (NB-818) 是一种新型二氢吡啶钙进入阻滞剂。
Cas No.:94739-29-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Lemildipine is a new dihydropyridine calcium entry blocker.
Gerbils are treated intraperitoneally with Lemildipine (0.1-3 mg/kg) just after release of the occlusion. Four days after the ischemia, they are fixed by perfusing 10% buffered-formalin, and the neuronal cell density (NCD, cell/mm) in the CA1 subfield is estimated under microscopy. The average NCD in the ischemic control group is 43±10.8 cells/mm, whereas Lemildipine (3 mg/kg) significantly ameliorates DND with an average NCD of 143±24.2 cells/mm (P<0.01). In addition, Lemildipine (3 mg/kg) significantly inhibits delayed neuronal death (DND) at 1, 2 and 4 weeks after transient ischemia: the average NCD of the Lemildipine and ischemic control groups are 80±9.4 (P<0.01) and 43±7.7 cells/mm, 92±13.7 (P<0.05) and 52±9.3 cells/mm, and 57±5.0 (P<0.01) and 43±12.4 cells/mm, respectively. In this experiment, Lemildipine (NB-818) exhibits a protective effect on DND in the hippocampal CA1 subfield after transient forebrain ischemia, and its effect persisted for up to 4 weeks[1]. In normal Wistar rats (NWR), Lemildipine (NPK-1886) in doses of 3-30 mg/kg, p.o., produces a mild lowering of blood pressure. The depressor effect of Lemildipine is much the same as that of Nifedipine. In contrast, Lemildipine produces a significant decrease in the blood pressure of spontaneously hypertensive rats (SHR). Oral administration of Lemildipine in doses of 3, 10, 30 mg/kg produces a significant decrease in systolic blood pressure dose-dependently. The maximum decrease is observed 1-3 hr after administration. Comparing the hypotensive potency of Lemildipine and Nifedipine, their dose-response curves at the maximum response during the observation (for 24 hr) are analyzed by the least squares method, and the dose of 30% decrease in blood pressure from the control level (ED30) are used as a measure of their potency. Lemildipine is 1.4 times stronger than Nifedipine; the ED30 values of Lemildipine and Nifedipine are 10.2 mg/kg and 14.3 mg/kg, respectively[2].
[1]. Kamei K, et al. Effect of a new calcium entry blocker, NB-818, on delayed neuronal death in the ischemic gerbil hippocampus. Jpn J Pharmacol. 1991 Jul;56(3):279-86. [2]. Nagura J, et al. Cardiovascular effects of NPK-1886, a new dihydropyridine compound with calcium entry blocking activity. Jpn J Pharmacol. 1986 Mar;40(3):399-409.
Animal experiment: | Gerbils[1] Male Mongolian gerbils, weighing 50-80g, are used in this experiment. Lemildipine (3 mg/kg) or vehicle is administered intraperitoneally just after the recirculation. At 1, 2 or 4 weeks after ischemia, the animals are sacrificed, and the protective effect of Lemildipine (NB-818) is examined. Mice and Rats[2] Normal Wistar rats (NWR) and hypertensive model rats (spontaneously hypertensive rats (SHR), renal hypertensive rats (RHR) and DOCA-saline-induced hypertensive rats (DOC-Na-R)) of the male sex, weighing from 250 to 350 g, are used. Oral administration of Lemildipine in doses of 3, 10, 30 mg/kg for normal Wistar rats (NWR). Lethal dose of Lemildipine and Nifedipine is determined by the Litchfield-Wilcoxon method from the data of experiments using healthy mice and rats. Mice (male and female) weighing 20±2 g and male rats weighing from 150 to 220 g are used. These two kinds of animals are fed on solid food (Crea, CA-1) and water ad lib. The animal room temperature and humidity are controlled at 22±2°C and 55±5%, respecttively. No food except water is administered 24 hr before starting the experiments for oral administration of drugs. |
References: [1]. Kamei K, et al. Effect of a new calcium entry blocker, NB-818, on delayed neuronal death in the ischemic gerbil hippocampus. Jpn J Pharmacol. 1991 Jul;56(3):279-86. | |
| Cas No. | 94739-29-4 | SDF | |
| 别名 | 来米地平,NB-818; NPK-1886 | ||
| Canonical SMILES | O=C(C1=C(COC(N)=O)NC(C)=C(C(OC)=O)C1C2=CC=CC(Cl)=C2Cl)OC(C)C | ||
| 分子式 | C20H22Cl2N2O6 | 分子量 | 457.3 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1867 mL | 10.9337 mL | 21.8675 mL |
| 5 mM | 0.4373 mL | 2.1867 mL | 4.3735 mL |
| 10 mM | 0.2187 mL | 1.0934 mL | 2.1867 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet